Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Mauna Kea Technologies's FCF Yield % or its related term are showing as below:
STU:1MK'
s FCF Yield % Range Over the Past 10 Years
Min: -132.36 Med: -24.77 Max: -3.8
Current: -12.94
During the past 13 years, the highest FCF Yield % of Mauna Kea Technologies was -3.80%. The lowest was -132.36%. And the median was -24.77%.
STU:1MK's FCF Yield % is ranked worse than 76.08% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: -0.4
vs STU:1MK: -12.94
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Mauna Kea Technologies FCF Yield % Related Terms
Mauna Kea Technologies FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mauna Kea Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies (STU:1MK) has a FCF Yield % of -12.94 as of Aug. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #649 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 76.1%.
Is Mauna Kea Technologies' FCF Yield % too high?
Mauna Kea Technologies' current FCF Yield % is -12.94. Based on the distribution chart, Mauna Kea Technologies ranks #649 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #649 out of 853 companies for FCF Yield %. This places Mauna Kea Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Mauna Kea Technologies and its competitors. Mauna Kea Technologies's current FCF Yield % is -12.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (STU:1MK) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.11, compared to a current price of €0.15 — trading 39.1% above its estimated fair value. The current FCF Yield % is -12.94. Mauna Kea Technologies' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Mauna Kea Technologies (STU:1MK), the current FCF Yield % is -12.94 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (STU:1MK) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 39.1% above its estimated GF Value™ of €0.11.
GuruFocus considers Mauna Kea Technologies to be Significantly Overvalued.
Key valuation signals for STU:1MK:
FCF Yield %: -12.94
GF Value™: €0.11 vs. price of €0.15 (39.1% above fair value)
No single metric tells the full story. See the STU:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
47GF Score
Get the complete analysis for STU:1MK
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1MK has been successfully added to your 
